Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids
Comparison of Healthcare Utilization and Costs in Patients With Asthma Who Fluticasone/Salmeterol Inhalation Powder Versus Other Inhaled Corticosteroid(s) in Typical Clinical Practice Using Health Insurance Claims Data.
1 other identifier
observational
5,180
0 countries
N/A
Brief Summary
The objective of this study is to compare healthcare utilization and costs in asthma patients who receive fluticasone propionate/salmeterol combination 100mcg/50mcg ("FSC 100/50") or inhaled corticosteriods in typical clinical practice using a retrospective observational cohort study design of large managed care database.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2009
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2009
CompletedFirst Submitted
Initial submission to the registry
March 4, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2010
CompletedFirst Posted
Study publicly available on registry
April 11, 2011
CompletedJune 2, 2017
June 1, 2017
1 year
March 4, 2010
June 1, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To assess the difference in asthma related exacerbations
Asthma related exaceberation is defined as any asthma related emergency department visit, or inpatient visit or oral corticosteroid dispensing.
90 days post index
Study Arms (1)
Asthma patients treated with inhaled corticosteroids
Asthma subjects newly prescribed inhaled corticosteriods
Interventions
Asthma subjects newly prescribed fluticasone propionate/salmeterol combination
asthma subjects newly prescribed inhaled corticosteroids in clinical practice
Eligibility Criteria
The study intends to identify subjects with asthma treated with inhaled corticosteroids
You may qualify if:
- Subjects with asthma as determined by ICD-9 codes and asthma drug use
- at least 12 years of age
- treated with inhaled corticosteroids
You may not qualify if:
- Subjects with COPD or treatment for COPD
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- GlaxoSmithKlinelead
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
GSK Clinical Trials
GlaxoSmithKline
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 4, 2010
First Posted
April 11, 2011
Study Start
June 1, 2009
Primary Completion
June 1, 2010
Study Completion
June 1, 2010
Last Updated
June 2, 2017
Record last verified: 2017-06